Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORINYL 1+50 28-DAY vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norethindrone and ethinyl estradiol combination works by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby inhibiting ovulation. Norethindrone also alters cervical mucus viscosity and endometrial lining, impeding sperm penetration and implantation.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy
Prevention of pregnancy
One tablet orally once daily for 28 days, with 7 inactive tablets during the last 7 days. Each active tablet contains norethindrone 1 mg and ethinyl estradiol 50 mcg.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Norethindrone: ~8-11 hours; Mestranol: 24 hours (prodrug, ethinyl estradiol half-life ~13-27 hours).
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Norethindrone is primarily metabolized via reduction to dihydro metabolites and glucuronide conjugation, with minor involvement of CYP3A4. Ethinyl estradiol is primarily metabolized by CYP3A4, with extensive first-pass metabolism and conjugation (sulfation and glucuronidation).
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal: ~40% as metabolites; Biliary/Fecal: ~60% as metabolites.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Norethindrone: ~80% bound to albumin and SHBG; Ethinyl estradiol: ~97% bound to albumin.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Norethindrone: ~4 L/kg; Ethinyl estradiol: ~15 L/kg, indicating extensive tissue distribution.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: Norethindrone ~64%; Ethinyl estradiol ~40-50% (due to first-pass metabolism).
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dosage adjustment is required for mild to moderate renal impairment. Use is contraindicated in patients with end-stage renal disease or on dialysis due to potential fluid retention and hypertension.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in patients with acute hepatitis, hepatic cirrhosis, or liver tumors (benign or malignant). For Child-Pugh Class A, use with caution; Class B or C: contraindicated due to impaired metabolism and risk of cholestasis.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Not indicated for use before menarche. For post-menarchal adolescents, dosing is the same as adults (one tablet daily). Safety and efficacy have not been established in prepubertal children.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for use in postmenopausal women due to lack of efficacy and increased cardiovascular risks. If used off-label, monitor for thromboembolism, hypertension, and hepatic effects.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives. This risk increases with age, particularly in women over 35 years, and with the number of cigarettes smoked. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Increased risk of thromboembolic events,Elevated risk of myocardial infarction and stroke especially in smokers >35,Hepatic neoplasia (benign and malignant) reported,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism alterations,Headache including migraine exacerbation,Uterine bleeding irregularities,Possible depression,Reduced efficacy with certain drugs such as enzyme inducers
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Known or suspected pregnancy,Current or history of venous thromboembolism,Current or history of arterial thrombotic disease,Uncontrolled hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms,Major surgery with prolonged immobilization,Hepatic impairment or active liver disease,Known or suspected breast cancer or other estrogen-sensitive neoplasia,Undiagnosed abnormal uterine bleeding,Cigarette smoking in women >35 years
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No specific food interactions. Grapefruit juice may increase estrogen levels (possible increased risk of side effects); avoid excessive consumption. Maintain consistent diet with regard to vitamin C intake as high doses may enhance estrogen absorption.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
Contraindicated in pregnancy. Category X: Use in first trimester has been associated with congenital defects including cardiovascular and limb defects. Exposure in second and third trimesters may cause fetal harm including masculinization of female fetuses due to androgenic progestin (norethindrone). Discontinue immediately if pregnancy occurs.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Small amounts of norethindrone and ethinyl estradiol are excreted in breast milk (M/P ratio for norethindrone ~0.6; ethinyl estradiol ~0.1). May reduce milk quantity and quality. Not recommended for breastfeeding mothers; consider alternative contraception.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
No dose adjustment applicable; drug contraindicated during pregnancy. Pharmacokinetic changes (e.g., increased volume of distribution, altered hepatic metabolism) are not relevant as therapy must be stopped. If accidental exposure, discontinue immediately and evaluate fetal risk.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
NORINYL 1+50 28-DAY (norethindrone 1 mg / mestranol 50 mcg) is a first-generation combined oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35. Use with caution in patients with migraine with aura. Breakthrough bleeding may occur; if persistent, rule out pregnancy or consider a pill with higher estrogen or different progestin. Missed pill protocol: if one pill missed, take it as soon as remembered; if two pills missed, take two pills for two days and use backup contraception for 7 days.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one pill daily at the same time each day. If you miss a pill, follow the missed pill instructions in the package insert.,Use backup contraception (e.g., condoms) if you miss two or more pills or start a new pack late.,This medication does not protect against sexually transmitted infections (STIs).,Avoid smoking while taking this medication, especially if you are over 35 years old, as it increases the risk of serious cardiovascular side effects.,Inform your healthcare provider if you experience severe headaches, chest pain, leg pain or swelling, vision changes, or jaundice.,If you experience persistent breakthrough bleeding, consult your healthcare provider.,Do not take this medication if you are pregnant or think you may be pregnant.,Store at room temperature away from moisture and heat.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORINYL 1+50 28-DAY vs ALYACEN 1/35, answered by our medical review team.
NORINYL 1+50 28-DAY is a Oral Contraceptive that works by Norethindrone and ethinyl estradiol combination works by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby inhibiting ovulation. Norethindrone also alters cervical mucus viscosity and endometrial lining, impeding sperm penetration and implantation.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORINYL 1+50 28-DAY and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORINYL 1+50 28-DAY is: One tablet orally once daily for 28 days, with 7 inactive tablets during the last 7 days. Each active tablet contains norethindrone 1 mg and ethinyl estradiol 50 mcg.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORINYL 1+50 28-DAY and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORINYL 1+50 28-DAY is classified as Category C. Contraindicated in pregnancy. Category X: Use in first trimester has been associated with congenital defects including cardiovascular and limb defects. Exposure in second and third. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.